187Rhenium-EC-G

**187Rhenium-EC-G** is an investigational radiopharmaceutical conjugate featuring the beta-emitting radioisotope rhenium-187 linked to EC-G, a chelator-ligand system designed for targeted delivery. It belongs to the class of radiopharmaceuticals leveraging high-energy beta emissions (similar to rhenium-188 analogs) for therapeutic destruction of diseased tissues, particularly in oncology, with potential theranostic applications due to rhenium's gamma emission suitable for imaging. Developed for precision radionuclide therapy, it targets cancer cells expressing specific antigens, enabling localized radiation while minimizing off-target effects; primary indications likely include solid tumors or metastases, though specific trials remain preclinical or early-stage.